Lexicon Pharmaceuticals (LXRX) Cash from Investing Activities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash from Investing Activities data on file, last reported at -$70.3 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 273.14% year-over-year to -$70.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 million (down 98.39% YoY) and the FY2025 annual result came in at $113.0 million, up 834.95% from the prior year.
• Cash from Investing Activities eased to -$70.3 million in Q1 2026 per LXRX's latest filing, from $4.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $53.7 million in Q4 2024 and bottomed at -$110.2 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $4.8 million (2025), against an average of -$5.5 million.
• The widest annual swing landed in 2022, when Cash from Investing Activities plunged 19199.0%; it then soared 374.34% in 2023.
• Tracing LXRX's Cash from Investing Activities over 5 years: stood at $24.2 million in 2022, then jumped by 114.69% to $51.9 million in 2023, then rose by 3.47% to $53.7 million in 2024, then plunged by 91.01% to $4.8 million in 2025, then slumped by 1554.72% to -$70.3 million in 2026.
• Per Business Quant, the three latest LXRX Cash from Investing Activities figures stand at -$70.3 million (Q1 2026), $4.8 million (Q4 2025), and $52.1 million (Q3 2025).

Peer Comparison